MARKET

IMMU

Immunomedics
IMMU
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-47.6258
895.25
34.20
20,309,431,352.12
Gilead Boosts Sales Forecast on Demand for Covid-19 Drug
Bloomberg · 08/02 20:08
Gilead Breast-Cancer Drug Delays Progression by 1.5 Months
Bloomberg · 06/04 12:00
Gilead Takes $2.7 Billion Writedown; Covid Drug Tops Estimates
Bloomberg · 04/28 20:27
Gilead’s Trodelvy Delays Progression of Common Breast Cancers
Bloomberg · 03/07 13:30
Gilead Shares Drop as Profit Guidance Falls Below Forecast
Bloomberg · 02/01 21:58
Gilead Says FDA Verdict on Outpatient Remdesivir Likely Soon
Bloomberg · 01/10 22:33
Omicron Spreading in U.S.; Gilead Recalls Vials: Virus Update
Bloomberg · 12/04/2021 04:11
Gilead Recalls 55,000 Vials of Covid Drug Due to Glass Shards
Bloomberg · 12/04/2021 00:06
More
No Data
Learn about the latest financial forecast of IMMU. Analyze the recent business situations of Immunomedics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
16.67%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMMU stock price target is 75.77 with a high estimate of 88.00 and a low estimate of 47.60.
High88.00
Average75.77
Low47.60
Current 87.86
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Institutional Holdings
Institutions: 393
Institutional Holdings: 236.75M
% Owned: 102.42%
Shares Outstanding: 231.16M
TypeInstitutionsShares
Increased
89
37.09M
New
138
18.44M
Decreased
82
26.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Chairman/Executive Director
Behzad Aghazadeh
Chief Financial Officer
Usama Malik
Chief Human Resource Officer
Kurt Andrews
Chief Accounting Officer
William Fricker
General Counsel/Secretary
Jared Freedberg
Executive Director
Scott Canute
Other
Bryan Ball
Other
Brendan Delaney
Other
Loretta Itri
Independent Director
Robert Azelby
Independent Director
Charles Baum
Independent Director
Barbara Duncan
Independent Director
Peter Hutt
Independent Director
Khalid Islam
No Data
No Data

Webull offers kinds of Immunomedics stock information, including NASDAQ:IMMU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMU stock methods without spending real money on the virtual paper trading platform.